BRAINAURORA-B (06681) announced that its wholly-owned subsidiary, Beijing Zhijingling Technology Co., Ltd. (Zhijingling Tech), as a key collaborator, has jointly participated in the national key R&D program "Prevention and Treatment Research of Cancer, Cardiovascular and Cerebrovascular, Respiratory, and Metabolic Diseases." The project, titled "Establishment and Scenario-Based Application of Key Digital Diagnosis and Treatment Technologies for Intracranial Atherosclerotic Stenosis-Related Cognitive Disorders Based on Deep Reasoning Large Models" (Project No.: 2025ZD0546200), has recently been officially launched.
Additionally, the "Beijing Key Laboratory for Digital Therapeutics in Cognitive Disorders," jointly applied for by Zhijingling Tech and Xuanwu Hospital of Capital Medical University, among others, has recently been approved. The company's involvement in the national key R&D program and the approval of the Beijing Key Laboratory highlight its leading technological position in the field of digital diagnosis and treatment for cognitive disorders.
Intracranial Atherosclerotic Stenosis (ICAS) has a high incidence rate of 13% among individuals aged 35 and above in China. ICAS-induced irreversible brain damage leads to cognitive dysfunction characterized by memory decline, language impairment, and executive dysfunction. Despite nearly half of moderate-to-severe ICAS patients experiencing cognitive impairment, effective early diagnosis and treatment methods remain lacking.
The newly launched national key R&D program focuses on addressing the challenges in diagnosing and treating ICAS-related cognitive disorders. Leveraging interdisciplinary advantages, the project will conduct systematic research, with core objectives including establishing an assessment technology system and deep reasoning predictive models for ICAS-related cognitive disorders. These tools aim to provide early disease screening, risk prediction, prevention, and intervention solutions, as well as a closed-loop management system for ICAS-related cognitive disorders.
The project, led by Xuanwu Hospital, involves collaboration with Peking Union Medical College Hospital, the Institute of Psychology under the Chinese Academy of Sciences, Jilin University, Beijing Normal University, and Zhijingling Tech. The research team comprises top experts in neurology, cognitive neuroscience, psychology, and artificial intelligence, with long-term partnerships with leading international research teams. Their prior publications in top-tier journals such as *Science* and *Cell* provide a solid foundation for the project's success.
National key R&D programs are major scientific initiatives aimed at achieving national strategic goals and breaking through core technologies. This project marks the elevation of digital diagnosis and treatment for neurocognitive disorders to a national strategic research level.
As a pioneer in integrating neuroscience and artificial intelligence, BRAINAURORA-B will leverage its technological and data expertise in digital diagnosis and treatment for neurological and psychiatric disorders to develop deep reasoning models for ICAS-related cognitive disorders and construct a digital diagnosis and treatment platform.
Furthermore, the Beijing Key Laboratory for Digital Therapeutics in Cognitive Disorders is a collaborative effort integrating clinical medicine, basic research, technology development, and hardware innovation. The company, as a core technology contributor, will focus on developing algorithms, productization, and optimizing user experience for the digital therapeutics platform. The laboratory will harness resources, including AI expertise, to advance core technologies, clinical translation, and industry standards while fostering academic exchange and talent development in digital therapeutics.